FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
1,872 letters match. Newest first.
-
DrugsHealBerry
FDA warned HealBerry that claiming compounded semaglutide has the 'same active ingredient as Ozempic and Wegovy' misbrands its drugs.
Medium -
DrugsReset IV, LLC dba Reset IV
FDA warned Reset IV that its website misbrands compounded semaglutide and tirzepatide by claiming they are the same as FDA-approved drugs.
Medium -
DrugsYangzhou Yulou Paper Products Co., Ltd.
FDA cited Yangzhou Yulou Paper Products for manufacturing violations after records showed its OTC sterile drugs lacked sterility assurance and testing.
High risk -
Drugsinspire.clinic
FDA warned telehealth site inspire.clinic that claims its compounded semaglutide and tirzepatide are similar to Ozempic or Mounjaro misbrand the drugs.
Low -
DrugsBioverse, Inc. dba Bioverse
FDA warned Bioverse that its website made false or misleading claims for compounded semaglutide and tirzepatide drugs.
Low -
DrugsSimpleRx
FDA warned SimpleRx that its website falsely implied compounded semaglutide and tirzepatide were Ozempic or Zepbound.
High risk -
DrugsElevate Your Wellness LLC, dba Elevated
FDA warned Elevated that its website offered compounded semaglutide and tirzepatide with misleading claims they match FDA-approved drugs.
Low -
DrugsCosmo Medical Spa dba Cosmo Med Spa
FDA warned Cosmo Med Spa over its website selling compounded semaglutide with claims implying it is FDA-approved Ozempic.
Medium -
DrugseDrugstore
FDA warns eDrugstore over claims that compounded tirzepatide is FDA-approved, making drugs misbranded (falsely promoted).
High risk -
DrugsNuvo Life Health Inc. dba Nuvo Life Health
FDA warned Nuvo Life Health that its website sold compounded semaglutide and tirzepatide with misleading claims comparing them to FDA-approved drugs.
Medium -
DrugsSemaBio
FDA warned SemaBio that its website sold compounded semaglutide and called it 'generic semaglutide,' a false or misleading claim.
Low -
Drugsdirectmeds.com, Inc. dba DirectMeds
FDA warned DirectMeds that its website sold compounded semaglutide and tirzepatide with false or misleading claims implying they match FDA-approved drugs.
High risk -
DrugsHims & Hers Health, Inc. dba Hims
FDA warns Hims that compounded semaglutide website claims are false or misleading and misbrand the drugs.
High risk -
DrugsMedClub by Dr. Jenn
FDA warns MedClub by Dr. Jenn over unapproved compounded retatrutide and misleading semaglutide claims on its website.
High risk -
DrugsMane & Steel, LLC. dba Mane & Steel
FDA warns Mane & Steel over false 'clinically proven' claims for compounded semaglutide.
Low -
DrugsLumimeds
FDA warns Lumimeds over website claims implying its compounded semaglutide and tirzepatide are FDA-approved.
High risk -
DrugsGLP-1 Solution
GLP-1 Solution sells unapproved compounded retatrutide online and misleadingly compares semaglutide and tirzepatide to FDA-approved brand drugs.
High risk -
DrugsASN-LABS
ASN-LABS marketed unapproved compounded retatrutide and misleading semaglutide claims online, FDA says.
High risk -
DrugsBody Good Studio
FDA warned Body Good Studio over its website selling compounded semaglutide with a false claim that it matches Ozempic and Wegovy.
High risk -
DrugsCanada Med Stop
Canada Med Stop marketed compounded semaglutide online as FDA-approved and generic, making the drugs misbranded.
Medium -
DrugsHealthy Male
FDA warns Healthy Male that its website sells compounded tirzepatide with false or misleading 'clinically proven' weight-loss claims.
Low -
DrugsInvigorate Med Spa
Invigorate Med Spa's website claimed compounded semaglutide and tirzepatide were Wegovy and Mounjaro, making them misbranded.
Low -
DrugsEA WORKS Limited Liability Company dba Trust Labs
FDA warned Trust Labs it sold unapproved compounded retatrutide and made false FDA-approval claims for semaglutide and tirzepatide online.
High risk -
DrugsFancy Meds, LLC dba Fancy Meds
FDA warns Fancy Meds that its compounded semaglutide and tirzepatide website claims are false or misleading.
Low -
DrugsMatthew Stern, CEO MyStart Health LLC.
FDA warns MyStart Health over 'Generic Ozempic' claims for compounded semaglutide.
Low -
DrugsElite Health Center
FDA warned Elite Health Center that its website falsely implied compounded semaglutide was FDA-approved, making the drugs misbranded.
Low -
DrugsCurex
FDA warned Curex that its website ads for compounded semaglutide and tirzepatide are false or misleading.
High risk -
BiologicsCSL Behring
FDA says CSL Behring's HIZENTRA TV ad overstates protection and plays down risks, misbranding the immune globulin biologic.
Medium -
DrugsEli Lilly and Company
FDA says Eli Lilly’s Oprah-linked video for Zepbound and Mounjaro misled on serious risks.
High risk -
DrugsNovo Nordisk Inc.
FDA says Novo Nordisk’s Oprah Winfrey video makes Wegovy, Ozempic and Victoza look safer than their labels allow.
High risk -
DrugsEli Lilly and Company
FDA says Eli Lilly's Zepbound online video omitted risk and limitations information and was not submitted to FDA.
High risk -
DrugsEli Lilly and Company
FDA says Eli Lilly's sponsored Zepbound video omitted risk and use information, misbranding the drug.
Low -
DrugsSomerset Therapeutics Private Limited
FDA cited Somerset Therapeutics' India plant for CGMP failures tied to a contaminated media fill and aseptic processing risks.
High risk -
DevicesSeniorLife Technologies, Inc.
FDA warns SeniorLife Technologies that its SeniorLife.AI app is unapproved and misbranded, with quality-system and reporting failures.
High risk -
FoodDingMoo LLC DBA Dingman’s Dairy
DingMoo LLC DBA Dingman’s Dairy lacked Foreign Supplier Verification Program records for imported frozen desserts and Pistachio Tartufo tied to a Salmonella outbreak.
High risk -
FoodMericon Industries, Inc.
Mericon Industries sold Florical and Meribin supplements with unapproved drug claims for osteoporosis and serious manufacturing and labeling failures.
High risk -
DrugsShirish M. Gadgeel, M.D.
Detroit clinical investigator Dr. Shirish Gadgeel enrolled ineligible subjects and missed required consent for genetic testing in drug trials.
High risk -
DrugsHikal Limited
FDA warned India's Hikal Limited that unresolved metal-particle complaints in its APIs and weak supplier oversight make its active ingredients adulterated.
High risk -
FoodJalisco Fresh Produce, Inc.
Jalisco Fresh Produce lacks required foreign supplier checks for imported jalapeno peppers and white onions, FDA says.
Medium -
DrugsAmneal Pharmaceuticals, LLC
FDA warns Amneal over visible particles in ropivacaine injection and inadequate investigations and endotoxin lab controls.
High risk -
DrugsGreen Vitality dba Gr33n
FDA warned Green Vitality dba Gr33n that its Jimerito Honey Eye Drops are an unapproved new drug sold with disease-treatment claims.
High risk -
DrugsHomeopathic Educational Services dba Homeopathic Family Medicine
FDA says Homeopathic Family Medicine sells unapproved Cineraria Maritima Eye Drops for cataracts online.
High risk -
DrugsSupply Center USA
Supply Center USA offered unapproved Similasan and Boiron eye drug products for sale online.
High risk -
DrugsWisconsin Pharmacal Company, LLC
FDA warns Wisconsin Pharmacal over OTC drug manufacturing violations, including released rejected product and S. aureus contamination.
High risk -
DrugsChromatography Institute of America dba Compounder’s International Analytical Laboratory
FDA warned Chromatography Institute of America, a Colorado contract drug testing lab, that sterility testing and quality controls violated current good manufacturing practice.
High risk -
AnimalSynergy Animal Products, Inc.
Synergy Animal Products marketed unapproved animal drugs for dairy cows with inadequate directions and major manufacturing violations.
High risk -
DevicesMiach Orthopaedics
FDA warns Miach Orthopaedics over quality-system failures in manufacturing its BEAR ACL Implant, including sterility monitoring and nonconforming product controls.
High risk -
BiologicsInnate Healthcare Institute
FDA warned Arizona clinic Innate Healthcare Institute for selling unapproved umbilical cord stem cells marketed to treat autism.
High risk -
FoodEurobread Inc. dba First Harvest
FDA found Eurobread/First Harvest lacked required foreign supplier verification for imported Mini Patisseries tied to a Salmonella outbreak.
High risk -
DevicesUscom Kft
Uscom Kft marketed SpiroSonic AIR spirometer in the U.S. without FDA clearance and had multiple quality system failures at its Budapest plant.
High risk